Laura Zanaboni

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

Antonio Piga, Renzo Galanello, Maria Domenica Cappellini et al. · PubMed · 2006 · 269 citations · Full text

Medicine, Hematology, Pharmacology +17

Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major

Marina Baldini, Stella Forti, Alessia Marcon et al. · Annals of Hematology · 2010 · 54 citations · Full text

Medicine, Endocrinology, Hematology +14

Combination of deferasirox and deferoxamine in clinical practice: An alternative scheme of chelation in thalassemia major patients

Elena Cassinerio, Nicola Orofino, Alberto Roghi et al. · Blood Cells Molecules and Diseases · 2014 · 49 citations

Medicine, Pharmacology, Pharmacotherapy +12

Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients

Elena Cassinerio, Alberto Roghi, Patrizia Pedrotti et al. · Annals of Hematology · 2012 · 48 citations

Medicine, Cardiology, Hematology +16

Abnormal Fundus Autofluorescence Results of Patients in Long-term Treatment with Deferoxamine

Francesco Viola, Giulio Barteselli, Laura Dell’Arti et al. · Ophthalmology · 2012 · 45 citations

Medicine, Internal Medicine, Ophthalmology +10